The EIF3CL Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from HeLa cells, engineered for targeted disruption of the EIF3CL gene. This loss-of-function model enables investigation of the non-core eukaryotic translation initiation factor 3 subunit L (EIF3CL) within a well-characterized cervical cancer cell system. The polyclonal format captures heterogeneous editing outcomes, offering a robust platform for functional genomics and translational control studies without clonal selection bias.
HeLa cells are an immortalized epithelial cell line originally established from a human cervical adenocarcinoma, harboring integrated human papillomavirus type 18 (HPV18) genomes. This cell line is a cornerstone of cancer research due to its rapid proliferation, high transfection efficiency, and extensively documented signaling networks. The EIF3CL knockout in this background provides a physiologically relevant context to study translation initiation dysregulation in HPV-driven malignancies and other solid tumors.
EIF3CL encodes a subunit of the multi-protein EIF3 complex, which orchestrates cap-dependent translation initiation by bridging mRNA to the 40S ribosomal subunit. It directly interacts with other EIF3 core subunits (A, B, D, E, F, G, H, I, J, K, M), the 40S ribosome, and components of the EIF4F complex, including EIF4E and EIF4G. Upstream signaling through mTORC1 and MAPK pathways, activated by growth factors such as EGF and insulin, regulates EIF4F assembly via 4E-BP1 and S6K phosphorylation. Disruption of EIF3CL impairs EIF3 complex integrity, attenuating translation of downstream proliferation-related mRNAs like CCND1 and MYC and reducing global protein synthesis. EIF3CL also contributes to pre-initiation complex formation with eIF1, eIF1A, eIF2, and Met-tRNAi, underscoring its role in scanning and start codon recognition.
In the HeLa cervical cancer model, elevated mTOR activity linked to HPV oncoproteins amplifies cap-dependent translation, positioning EIF3CL as a critical regulatory node. The polyclonal EIF3CL knockout enables precise dissection of this subunit??s contribution to translation reprogramming and cancer cell growth without the adaptation artifacts of clonal isolates. It serves as a model to evaluate how EIF3 complex stoichiometry and function influence protein synthesis-dependent oncogenic signaling, cell viability, and sensitivity to translational inhibitors.
Research applications include polysome profiling to assess ribosome occupancy, translational reporter assays to quantify cap-dependent translation efficiency, RNA-seq for transcriptome-wide changes, and Western blotting or RT-qPCR for target gene expression analysis. The system supports cell proliferation assays and target validation for inhibitors of mTOR signaling or the translational machinery. For further technical information or customized solutions, please contact Ascent Research.
